• In recent months, Moderna reported strong Phase 3 data showing its mRNA-1010 flu vaccine outperformed standard shots in adults 50 and older, while publishing early-stage but encouraging results for its hantavirus vaccine program amid heightened concern following a cruise ship outbreak.
• Together with fresh recognition for its mRNA platform and expanded pandemic-preparedness partnerships, these developments highlight how Moderna is working to diversify beyond COVID-19 and position its technology for emerging infectious threats.
• Next, we’ll examine how the strong mRNA-1010 Phase 3 flu results may influence Moderna’s existing investment narrative and risk profile.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Moderna Investment Narrative Recap

To own Moderna, you need to believe its mRNA platform can produce multiple successful products beyond COVID-19 and eventually reduce heavy reliance on a seasonal vaccine cycle. The key near term catalyst is the upcoming FDA decision on mRNA-1010, since strong Phase 3 data in older adults directly supports Moderna’s push to broaden its respiratory franchise. The biggest risk remains that new launches do not ramp fast enough to offset COVID-19 volatility, keeping losses wide.

Among recent announcements, the publication of Phase 3 flu data in the New England Journal of Medicine stands out. It ties directly into the mRNA-1010 review and helps Moderna argue that its flu shot offers better protection than standard vaccines in adults 50 and over. How regulators and payers respond to that evidence will influence whether flu meaningfully stabilizes revenue, especially as the company continues to post sizeable net losses despite periodic revenue beats.

Yet even with flu momentum, investors should be aware that Moderna still faces concentrated respiratory exposure and regulatory uncertainty around vaccine uptake and pricing...

Moderna's narrative projects $3.2 billion revenue and $407.1 million earnings by 2029.

Uncover how Moderna's forecasts yield a $46.10 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were assuming revenue could climb to about US$7.9 billion by 2029 and turn losses into profit, may see the latest flu and hantavirus updates as reinforcing that upside, while others will focus more on regulatory and adoption risks; as a shareholder, you are weighing which of these very different stories feels closer to reality.

Explore 6 other fair value estimates on Moderna - why the stock might be worth 12% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.